TY - JOUR
T1 - Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
AU - Palumbo, AA
AU - Dimopoulos, M
AU - Miguel, JS
AU - Harousseau, JL
AU - Attal, M
AU - Hussein, M
AU - Knop, S
AU - Ludwig, H
AU - von Lilienfeld-Toal, M
AU - Sonneveld, Pieter
PY - 2009
Y1 - 2009
N2 - Recent studies have shown a clinical benefit of lenalidomide, an oral immunomodulatory drug, plus dexamethasone in patients with relapsed/refractory multiple myeloma (MM). The most common grade 3-4 adverse events were cytopenias, fatigue, muscle cramps, rash, infection, insomnia, and venous thromboembolism. Lenalidomide in combination with dexamethasone has been approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of patients with MM who have received at least one prior therapy. An expert panel reviewed the efficacy and toxicity of lenalidomide plus dexamethasone, and provided recommendations on the management of patients receiving this treatment. Patient selection is straightforward, as prognostic factors do not appear to heavily influence efficacy. In addition, the panel agreed on strategies for the management of side effects. The recommendations presented here will aid the safe administration of lenalidomide, and avoid unnecessary dose reduction and discontinuation, thus assuring the best efficacy of treatment. (c) 2008 Elsevier Ltd. All rights reserved.
AB - Recent studies have shown a clinical benefit of lenalidomide, an oral immunomodulatory drug, plus dexamethasone in patients with relapsed/refractory multiple myeloma (MM). The most common grade 3-4 adverse events were cytopenias, fatigue, muscle cramps, rash, infection, insomnia, and venous thromboembolism. Lenalidomide in combination with dexamethasone has been approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of patients with MM who have received at least one prior therapy. An expert panel reviewed the efficacy and toxicity of lenalidomide plus dexamethasone, and provided recommendations on the management of patients receiving this treatment. Patient selection is straightforward, as prognostic factors do not appear to heavily influence efficacy. In addition, the panel agreed on strategies for the management of side effects. The recommendations presented here will aid the safe administration of lenalidomide, and avoid unnecessary dose reduction and discontinuation, thus assuring the best efficacy of treatment. (c) 2008 Elsevier Ltd. All rights reserved.
U2 - 10.1016/j.blre.2008.07.003
DO - 10.1016/j.blre.2008.07.003
M3 - Article
SN - 0268-960X
VL - 23
SP - 87
EP - 93
JO - Blood Reviews
JF - Blood Reviews
IS - 2
ER -